

```

source
1. 421
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:782283"
/clone_1ib="Soares_testis_NHT"
/sex="male"
/lab_host="DH10B"
/note="Vector: pT7T3D-Pac (Pharmacia) with a modified
polylinker; Site.1: Not I; Site.2: Eco RI; 1st strand cDNA
was prepared from mRNA obtained from Clontech Laboratories
, Inc., and primed with a Not I - oligo(dT) primer [5'].
TGTTCACCAATGTGAAGTGGAGACGGCCGCCCAATTTTCTTTTCTT 3'}.
Double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization to Cot5, and was
constructed by bento Soares and M. Fatima Bonaldo. "
BASE COUNT      148 a
ORIGIN           66 c      51 g      156 t
Query Match      100.0%; Score 421; DB 9; Length 421;
Best Local Similarity 100.0%; Pred. No. 4 1e-56;
Matches 421; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

RESULT 1
ABL65541 standard; DNA; 421 BP.

for seq 857

XX ABL65541;
AC
XX
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:3878.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilms tumour; adenocarcinoma;
KW gene; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200194629-A2.
PN
XX
XX 13-DEC-2001.
PD
XX
XX 30-MAY-2001; 2001WO-US10838.
PF
XX
XX 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR

A0665741

- cont -

PR 25-SEP-2000: 2000US-234923P
 PR 25-SEP-2000: 2000US-234924P
 PR 25-SEP-2000: 2000US-235077P
 PR 25-SEP-2000: 2000US-235082P
 PR 25-SEP-2000: 2000US-235134P
 PR 25-SEP-2000: 2000US-235280P
 PR 26-SEP-2000: 2000US-235637P
 PR 26-SEP-2000: 2000US-235638P
 PR 27-SEP-2000: 2000US-235711P
 PR 27-SEP-2000: 2000US-235720P
 PR 27-SEP-2000: 2000US-235840P
 PR 27-SEP-2000: 2000US-235863P
 PR 28-SEP-2000: 2000US-236028P
 PR 28-SEP-2000: 2000US-236032P
 PR 28-SEP-2000: 2000US-236033P
 PR 28-SEP-2000: 2000US-236034P
 PR 28-SEP-2000: 2000US-236109P
 PR 28-SEP-2000: 2000US-236111P
 PR 29-SEP-2000: 2000US-236842P
 PR 29-SEP-2000: 2000US-236891P
 PR 02-OCT-2000: 2000US-237172P
 PR 02-OCT-2000: 2000US-237173P
 PR 02-OCT-2000: 2000US-237278P
 PR 02-OCT-2000: 2000US-237294P
 PR 02-OCT-2000: 2000US-237295P
 PR 02-OCT-2000: 2000US-237316P
 PR 03-OCT-2000: 2000US-237425P
 PR 03-OCT-2000: 2000US-237598P
 PR 03-OCT-2000: 2000US-237604P
 PR 03-OCT-2000: 2000US-237606P
 PR 03-OCT-2000: 2000US-237608P
 PR 01-NOV-2000: 2000US-244867P
 PR 01-NOV-2000: 2000US-245084P
 XX
 PA (AVAL-) AVALON PHARM.
 XX
 PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX
 DR WPI: 2002-188264/24.
 XX
 PT Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 XX determining a change in expression of a gene of a signature gene set
 PS Claim 1: SEQ ID 3878: 44pp: English.
 XX
 CC The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in ABL6164
 CC to ABL70110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
 CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
 CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilms' tumour.
 XX
 SQ Sequence 421 BP: 148 A; 66 C; 51 G; 156 T; 0 other;

Query Match 100.0%; Score 421; DB 24; Length 421;
 Best Local Similarity 100.0%; Pred No 4,4e-74;
 Matches 421: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

-0Y 1 TTTTTCATTTTTCATTTGAAATGCTTAAATAGTGTGACACACTGTTTGCAA 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||

Db 1 TTTTTCATTTTTCATTTGAAATGCTTAAATAGTGTGACACACTGTTTGCAA 60
 QY 61 AATGTAAGATACATATACAAATTCCTTAATACAAAAGAAATTAATTAAGACATTTCTT 120
 Db 61 AATGTAAGATACATATACAAATTCCTTAATACAAAAGAAATTAATTAAGACATTTCTT 120
 QY 121 TTTTAAATTCGCAACTTGTCTACAGTACATCTTTTCATTTGATTCAGTTGACAG 180
 Db 121 TTTTAAATTCGCAACTTGTCTACAGTACATCTTTTCATTTGATTCAGTTGACAG 180
 QY 181 AATCCAGTAAATATCTTTTACATGCTCTACAGTACAGTTCAGGACCACTAATCTTTT 240
 Db 181 AATCCAGTAAATATCTTTTACATGCTCTACAGTACAGTTCAGGACCACTAATCTTTT 240
 QY 241 TCCCCATTTAATACAGTACAGTTCATTTTACAACTTGTAAATTAATTCATTAAT 300
 Db 241 TCCCCATTTAATACAGTACAGTTCATTTTACAACTTGTAAATTAATTCATTAAT 300
 QY 301 GTATATGTAAACTTTACACCTAGTATACAGTACAGTTCATTCATTCAGTACAGCTG 360
 Db 301 GTATATGTAAACTTTACACCTAGTATACAGTACAGTTCATTCATTCAGTACAGCTG 360
 QY 361 GATGGGTTTGTCTATTTTGAACCTAATTAATTAATTAATTAATTAATTAATTAAT 420
 Db 361 GATGGGTTTGTCTATTTTGAACCTAATTAATTAATTAATTAATTAATTAATTAAT 420
 QY 421 A 421
 Db 421 A 421

ALIGNMENTS

for SEU 12 NO: 995

RESULT 1
ABL65685
ID ABL65685 standard; DNA; 327 BP.
XX
AC ABL65685;
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:4022.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN MO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001MO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

us-09-954-

```

Query Match          100.0%   Score 327   DR14   length 327.
BASE COUNT          98 a      71 c      74 g      84 t
ORIGIN
Seq primer: Promega -21m13
High quality sequence stop: 305.
Location/Qualifiers
1. 327
/organism="Homo sapiens"
/db_xref="GDB:424323"
/db_xref="taxon:9606"
/clone="IMAGE:51513"
/clone_lib="Soares Infant brain INIB"
/sex="female"
/dev_stage="73 days post natal"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: Whole brain; Vector: Lactimid BA; Site:1: Not
I; Site:2: Hind III; 1st strand cDNA was primed with a Not
I - oligo(4T) primer [5',
AAGCTGGAAGAATTCGGCGCGCAGCAATTTTTTTTTTTTTTTT 3'];
double-stranded cDNA was ligated to Hind III adaptors
(Pharmacia), digested with Not I and directionally cloned
into the Not I and Hind III sites of the Lactimid BA vector.
Library went through one round of normalization. Library
constructed by Bento Soares and M.Fatima Bonaldo."

```

RESULT 6
LOCUS
AM967462
DEFINITION EST379537 MAGE resequences, MAGJ Homo sapiens CDNA, EST 01-JUN-2000
ACCESSION AM967462
VERSION AM967462
KEYWORDS EST
SOURCE human
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 591)
Hegde, P., Qi, R., Abernathy, K., Dharp, S., Gaspard, R., Gay, C., Holt
I.E., Saeed, A.I., Sharov, V., Lee, N.H., Yeatman, T.J. and
Quackenbush, J.
TITLE Assessment of gene expression patterns in a model of colon tumor
JOURNAL Unpublished (2000)
COMMENT Contact: John Quackenbush
The Institute for Genomic Research
7912 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 3528
Fax: 301 838 0208
Email: johnq@ligr.org
Plate: 241
Seq primer: Forward
FEATURES
Location/Qualifiers
1.591
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="MAGE resequences, MAGJ"
/note="Vector: pBluescriptSKM"
204 a 95 c 96 g 196 t
BASE COUNT

Query Match
Best Local Similarity 100.0%; Score 376; DB 10; Length 591;
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AACATTAAGATTCTTATTAACAAACCATGCAATTTATATATATTTCTTACACTTAAGGAATAGAT 61
DB 1 AACATTAAGATTCTTATTAACAAACCATGCAATTTATATATATTTCTTACACTTAAGGAATAGAT 60
QY 62 ATGAACAATCTTGGAGTAAATAAGGCAACCTTGGCTTCAAGCTTGAAGGATCTCA 121
DB 61 ATGAACAATCTTGGAGTAAATAAGGCAACCTTGGCTTCAAGCTTGAAGGATCTCA 120
QY 122 TCAAGCAGAAACCTGTAAGAAACCTTGGCTTGAAGGATCTCAAGGATCTCA 181
DB 121 TCAAGCAGAAACCTGTAAGAAACCTTGGCTTGAAGGATCTCAAGGATCTCA 180
QY 182 TTTCTTCCAAATGAATAAATGAAGTCAATGTCCTTGAAGGATCTCAAGGATCTCA 241
DB 181 TTTCTTCCAAATGAATAAATGAAGTCAATGTCCTTGAAGGATCTCAAGGATCTCA 240
QY 242 ATGAAGAAGCATTTTGAAGGATCTCAAGGATCTCAAGGATCTCAAGGATCTCA 301
DB 241 ATGAAGAAGCATTTTGAAGGATCTCAAGGATCTCAAGGATCTCAAGGATCTCA 300
QY 302 AAAAAAATATCTTAATCCCTATTAACAACATCCCAAAATTCAGATTTTAATTAAGTTA 361
DB 301 AAAAAAATATCTTAATCCCTATTAACAACATCCCAAAATTCAGATTTTAATTAAGTTA 360
QY 362 GGCCCTGGGCATATAG 377
DB 361 GGCCCTGGGCATATAG 376

Seq ID No: 1621

ALIGNMENTS

for SEQ ID NO 1621

```
RESULT 1
ABL65308
ID ABL65308 standard; DNM: 377 BP.
XX
XX
AC ABL65308;
XX
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:3645.
XX
KW Human; Cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
XX
PN W0200194629-A2.
XX
XX
PD 13-DEC-2001.
XX
XX
PF 30-MAY-2001; 2001MO-US10838.
XX
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
```


ALIGNMENTS

RESULT 1
ID ABL64298 standard; DNA; 418 BP. *ES - 522 bp N. 1612*
XX ABL64298;
AC
XX
DT 15-MAY-2002 (first entry)
XX
DE Stomach cancer related gene sequence SEQ ID NO:2635.
XX
KW Human; Cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
XX gene; ds.
OS Homo sapiens.
XX
PN W0200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001NO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

US-09-954

```

FEATURES
High quality sequence stop: 362.
Location/Qualifiers
1. 418
/Organism="Homo sapiens"
/db_xref="GDB:1239454"
/db_xref="taxon:9606"
/clone="IMAGE:294533"
/clone_lib="Soares fetal liver spleen INFLS"
/sex="male"
/dev_stage="20 week post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: Liver and Spleen; Vector: p7T73D (Pharmacia)
with a modified polylinker; Site_1: Pac I - oligo(dT) primer
1st strand cDNA was primed with a Pac I - oligo(dT) primer
15' AACGCGAGCAATTAATTAAAGACTCTTTTTTTTTTTTTTTTTT 3'),
double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Pac I and cloned into the Pac I
and Eco RI sites of the modified p7T73 vector. Library
went through one round of normalization. Library
constructed by Bento Soares and M.Fátima Bonaldo."
BASE COUNT
159 a      74 c      89 g      95 t      1 others
ORIGIN

```

ALIGNMENTS

for SEQ ID NO: 1360

```

RESULT 1
ABL65990
ID ABL65990 standard; DNA; 436 BP.
XX
AC ABL65990;
XX
DT 15-MAY-2002 (first entry)
DE
XX Lung cancer related gene sequence SEQ ID NO:4327.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens;
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234099P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

```


us-09-954-

```

FEATURES
Source
High quality sequence stop: 185.
Location/Qualifiers
1.436
/organism="Homo sapiens"
/db_xref="GDB:5975360"
/db_xref="taxon:9606"
/clone_id="IMAGE:752528"
/clone_id="Scars_NbHMPu_S1"
/tissue_type="Pooled human melanocyte, fetal heart, and
pregnant uterus"
/lab_host="DH10B"
/note="Organ: mixed (see below); Vector: pRT73D-Pac
(Pharmacia) with a modified polylinker; Site_1: Not I;
Site_2: Eco RI; Equal amounts of plasmid DNA from three
normalized libraries (melanocyte 2NbHm, pregnant uterus
NbHmpu, and fetal heart NbHHL9w) were mixed, and ss circles
were made in vitro. Following HAP purification, this DNA
was used as tracer in a subtractive hybridization
reaction. The driver was PCR-amplified cDNAs from pools of
5,000 clones made from the same 3 libraries. The pools
consisted of I.M.A.G.E. clones 260232-265223,
340488-345479, and 484488-489479."
BASE COUNT
143 a
88 c 90 g 115 t
ORIGIN

```

ALIGNMENTS

RESULT 1

AA620885

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

AA620885 383 bp mRNA linear EST 02-MAR-1998

af95g06.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1055578

3' mRNA sequence.

AA620885

EST.

human.

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 383)

Hiller, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,

Kizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin

J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,

White, Y., Wylie, T., Waterston, R. and Wilson, R.

Washington University School of Medicine

Contact: Wilson RK

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

This clone is available royalty-free through INL; contact the

IMAGE Consortium (info@image.lnl.gov) for further information.

Insert length: 1052 Std Error: 0.00

Seq primer: -40ml3 fwd. ET from AmerSham

4- SEQ 16 NO: 1346

RESULT 4

LOCUS

DEFINITION

q15a11.x1 NCI-CGAP-UT3 Homo sapiens cDNA clone IMAGE:1991132 3'

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens

human

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (1997)

Contact: Robert Strausberg, Ph.D.

Email: cgaabs-r@mail.nih.gov

Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.

CDNA Library Preparation: Life Technologies, Inc.

CDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center

Cloned through the I.M.A.G.E. Consortium/LNL at:

www.bio.lnu.edu.gov/bbrp/image/image.html

Insert length: 3608 Std Error: 0.00

Seq primer: -400P from gibco

High quality sequence stop: 399

Location/Qualifiers

1. 413

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:1991132"

/clone_lib="NCI-CGAP-UT3"

/issue_type="poorly-differentiated endometrial

adenocarcinoma, 2 pooled tumors"

/lab_host="DH10B"

/note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: Salt;

Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.

Average insert size 1.45 kb. Life Technologies catalog #:

BASE COUNT

157 a 68 c 46 g 142 t

Query Match

Best Local Similarity 99.7%; Pred. No. 3.3e-58;

Matches 382; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 TTTGACATATAAATTTCTTTTAACTTAATCCACCGAGTATAGTTCCTATA 60

DB 5 TTTTACATATAAATTTCTTTTAACTTAATCCACCGAGTATAGTTCCTATA 64

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

QY

Tue May 27 08:34:32 2003

us-09-954-

P1 Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S,
P1 Soppe, DR, Weaver Z,
XX
XX
XX WPI; 2002-188264/24.

XX The present invention describes a method (M1) for screening for an anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (I) of a signature gene set, where (I) comprises a sequence (S) selected from 8447 sequences (given in AB61664 to AB170110), or is at least 95% identical to (S), where a change in expression is indicative of anti-neoplastic activity. (I) has cytosolic activity and can be used in gene therapy. M1 can be used for screening an anti-neoplastic agent, and can be used for producing a product which is the data collected with respect to the anti-neoplastic agent as a result of M1, and the data is sufficient to convey the chemical structure and/or properties of the agent. M1 can be used in the treatment of cancer such as colon, breast, stomach, lung, thyroid, CC oesophageal, ovarian, kidney, prostate or pancreatic cancer, CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal carcinoma, papillary carcinoma and Wilms' tumour.

XX Sequence 383 BP; 153 A; 60 C; 47 G; 123 T; 0 other;

Query Match 100.0%; Score 82.24;
Best Local Similarity 100.0%; Pred No. 5, Bn 25;
Matches 383; Length 383;

us-09-954-45

Db	1	TTTGACACATAAAATTCCTTTATTTAAACCTTAATCCAGCCAGTATTGACATCGTTGGCTATA	60
Qy	61	TTTAAAAACACAGCGTTTAAAAAAATTCACGCAAAAGTAGACAGCGAGTACCTAATTAAGT	120
Db	61	TTTAAAAACACAGCGTTTAAAAAAATTCACGCAAAAGTAGACAGCGAGTACCTAATTAAGT	120
Qy	121	CACAAAGTTAAATTTATTTATTTCTTCACAGTCATTTCAATAATCATGTAAAGTAAACAATA	180
Db	121	CACAAAGTTAAATTTATTTATTTCTTCACAGTCATTTCAATAATCATGTAAAGTAAACAATA	180
Qy	181	TTTTCCGCCACTTTGGAGATPAAGTTAACTTTGAAAAGAAATTAATATTTCTGTAGTGTCA	240
Db	181	TTTTCCGCCACTTTGGAGATPAAGTTAACTTTGAAAAGAAATTAATATTTCTGTAGTGTCA	240
Qy	241	TTGTAATTTTATTAAGAAGGTTTAAACATTTAAAGTTTCCGAATATPAACAGTAAAGAAA	300
Db	241	TTGTAATTTTATTAAGAAGGTTTAAACATTTAAAGTTTCCGAATATPAACAGTAAAGAAA	300
Qy	301	TATTAATAAATTAACATCGGAAAAATTAATAATATACCCACCCATCGAAAAAATCTACATCATCTCT	360
Db	301	TATTAATAAATTAACATCGGAAAAATTAATAATATACCCACCCATCGAAAAAATCTACATCATCTCT	360
Qy	361	TTTCATTTGTGCCCAATGCCCTTTC	383
Db	361	TTTCATTTGTGCCCAATGCCCTTTC	383

N52026 486 bp mRNA linear EST 15-FEB-1996
yz08e07.s1 Soares_multiple_sclerosis_2NBHMSF Homo sapiens cDNA
clone IMAGE:282468 3', mRNA sequence.
N52026
N52026.1 GI:1193192
EST.
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 486)
Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman
, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J.,
Rifkin, B., Rohlfing, T., Soares, M., Tan, F., Trevasias, E., Waterson
, R., Williamson, A., Wohlmann, P. and Wilson, R.
The WashU-Merck EST Project
Unpublished (1995)
Contact: Wilison RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: m13 -40 forward
High quality sequence stop: 194.

US-09-954

Location/Qualifiers
1. .486

	0. DECADE (MINDS/MIH).	
157 a	85 c	94 g
		147 t
		3 others

Query Match	99.4%	Score 483	DB 14	Length 486
Best Local Similarity	100.0%	Pred. No. 2,4e-118		
Matches	486	Conservative	0	Mismatches 0
				Indels 0
				Gaps 0

QY	1	ACCCGTGAGTATAGAAATAGATTATTATAGCAAGAGGTAAATCGAAGCAACATATATTTTACAA	60
Db	1	ACCCGTGAGTAAATAGATTATTATAGCAAGAGGTAAATCGAAGCAACATATATTTTACAA	60
QY	61	AATGGAATTTTTTTCCAAACAAGCTGTAAATATTTTATAGACTTGAATAGAAAT	120
Db	61	AATGGAATTTTTTTTCCAAACAAGCTGTAAATATTTTATAGACTTGAATAGAAAT	120
QY	121	TCTCATACCACTAGGATATTGCTTACAGCAAAAGTGTCTGTCTGTTGTATAGTGCATATGC	180
Db	121	TCTCATACCACTAGGATATTGCTTACAGCAAAAGTGTCTGTCTGTTGTATAGTGCATATGC	180
QY	181	CTGCCACTTGGAGTTAACTGTGTTTCTATCTGTACGTACAGTGTAAATAATACATAGCTAA	240
Db	181	CTGCCACTTGGAGTTAACTGTGTTTCTATCTGTACAGTGTAAATAATACATAGCTAA	240
QY	241	TATTCACAGAAATTAAGCACTACATTACTATATTCCTGTACAGCAAGCATTTAGACAGAGCTA	300
Db	241	TATTCACAGAAATTAAGCACTACATTACTATATTCCTGTACAGCAAGCATTTAGACAGAGCTA	300
QY	301	CAGTATATGCGATATAAAACACTGTGTTATGTGATTTTCCATATCTCTACAGTGTGGTA	360
Db	301	CAGTATATGCGATATAAAACACTGTGTTATGTGATTTTCCATATCTCTACAGTGTGGTA	360
QY	361	CTAATATATCCACCACCAAGGTATACNGGACTTAAGGCCATCTCTCAATGTAAAGCCTTGTA	420
Db	361	CTAATATATCCACCACCAAGGTATACNGGACTTAAGGCCATCTCTCAATGTAAAGCCTTGTA	420
QY	421	AGTGACCCGTTTANGACGCTTAAAGANGAAAAAGTACATTTTGTGGGTTTCCCCGACTT	480
Db	421	AGTGACCCGTTTANGACGCTTAAAGANGAAAAAGTACATTTTGTGGGTTTCCCCGACTT	480
QY	481	TCAGTG 486	
Db	481	TCAGTG 486	

ALIGNMENTS

for SETA ID NO: 1483

RESULT 1

ABL66173

ID ABL66173 standard; DNA; 486 BP.

AC ABL66173;

DT 15-MAY-2002 (first entry)

DE Lung cancer related gene sequence SEQ ID NO:4510.

KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;

KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;

KW cytosolic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;

KW gene; ds.

XX Homo sapiens.

PN WO200194629-A2.

PD 13-DEC-2001.

PF 30-MAY-2001; 2001WO-US10838.

XX.

PR 05-JUN-2000; 2000US-209473P.

PR 05-JUN-2000; 2000US-209531P.

PR 18-SEP-2000; 2000US-233133P.

PR 18-SEP-2000; 2000US-233617P.

PR 20-SEP-2000; 2000US-234009P.

PR 20-SEP-2000; 2000US-234034P.

PR 22-SEP-2000; 2000US-234509P.

PR 22-SEP-2000; 2000US-234567P.

Db	1	ACCCGTGATGATGATGATTTATTATGACAAGGTAATACAGAAACAATATTTTTCACA	60
Qy	61	AATGGAAATTTTTTCCCAACAGCTTAAGTGAATATTTTACGCTTGAATATGAAAT	120
Db	61	AATGGAAATTTTTTCCCAACAGCTTAAGTGAATATTTTACGCTTGAATATGAAAT	120
Qy	121	TCTCATACCACTAGTAGTATTCCTTCACCAAAAGTGTCTGTCTGTATGTGGAGATGC	180
Db	121	TCTCATACCACTAGTAGTATTCCTTCACCAAAAGTGTCTGTCTGTATGTGGAGATGC	180
Qy	181	CTGCCACTTCGGAGTTAACTGTGTCTTCTATACGTACAGTGAATAAATAACATGGTAA	240
Db	181	CTGCCACTTCGGAGTTAACTGTGTCTTCTATACGTACAGTGAATAAATAACATGGTAA	240
Qy	241	TATTCACGAATTAAGCACTACATTAATATATTCCTGTAAAGGCATTTAGACAGACATA	300
Db	241	TATTCACGAATTAAGCACTACATTAATATTCCTGTAAAGGCATTTAGACAGACATA	300
Qy	301	CAGTATATGCCATPAAAAACACTTGTTGTTATTTGATTTTCCCTAATTTCCCTACAGTGTGGTA	360
Db	301	CAGTATATGCCATPAAAAACACTTGTTGTTATTTGATTTTCCCTAATTTCCCTACAGTGTGGTA	360
Qy	361	CTAATTTTCCCAAGGTATACNGAGCTTAAGGCATCTCTCAATGTAAAGCCTTGTA	420
Db	361	CTAATTTTCCCAAGGTATACNGAGCTTAAGGCATCTCTCAATGTAAAGCCTTGTA	420
Qy	421	AGTGACCGGTANACAGCCTTAAAGANGAAAAAGTACATTTTGGGTGTCCCCGACTT	480
Db	421	AGTGACCGGTANACAGCCTTAAAGANGAAAAAGTACATTTTGGGTGTCCCCGACTT	480
Qy	481	TCAGTG 486	
Db	481	TCAGTG 486	

ALIGNMENTS

for SEA ID NO 1549

RESULT 1

H98215

LOCUS

383 bp

mRNA

linear

EST 12-DEC-1995

DEFINITION

H98215
Y090402.s1 Soares melanocyte 2NDHM Homo sapiens cDNA clone
IMAGE:261194 3', mRNA sequence.

ACCESSION

H98215

H98215.1 GI:1119100

VERSION

EST

KEYWORDS

human.

SOURCE

Homo sapiens

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria;

Primates; Catarrhini; Hominoidea; Homo.

1 (bases 1 to 383)

Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman

M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J.,

Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaskis, E., Waterston

R., Williamson, A., Wohldmann, P. and Wilson, R.

The WashU-Merck EST Project

Unpublished (1995)

Contact: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@wustl.edu

High quality sequence stops: 109

Source: IMAGE Consortium, LLNL

This clone is available royalty-free through LLNL; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.

Insert Length: 1053 Std Error: 0.00
Seq primer: m13 -40 forward
High quality sequence stop: 109.
Location/Qualifiers
1. 383

FEATURES

/organism="Homo sapiens"
/db_xref="GDB:3870836"
/db_xref="taxon:9606"
/clone="IMAGE:261194"
/clone.lib="Soares melanocyte 2NBHM"
/sex="Male"
/tissue="type="melanocyte"
/lab_host="DH10B (ampicillin resistant)"
/note="Vector: pT73D (Pharmacia) with a modified
polylinker. Site 1: Not I; Site 2: Eco RI; 1st strand cDNA
was primed with a Not I - oligo(dT) primer (5'
TCTTCAATCTGAAGTGGAGCGGCGCCAGTCTTTTCTTTTCTTTT
3'),
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pT73 vector
(Pharmacia). Library constructed by Bento Soares and
M. Fatima Bonaldo. RNA from normal foreskin melanocytes
(FS374) was kindly provided by Dr. Anthony P. Albino."

BASE COUNT 139 a 65 c 80 g 96 t 3 others
ORIGIN

Query Match 99.2% Score 380; DB 14; Length 383;
Best Local Similarity 100.0%; Pred. No. 9.2e-92;
Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CACAGGAACAATCTTTTATGTACATGGAGAAATGACCCCTGCTGCTCAAGTG 60
1 CACAGGAACAATCTTTTATGTACATGGAGAAATGACCCCTGCTGCTCAAGTG 60
61 CACATACAGAAATTTGATTAAGAAAGAGGAAAGGGAAGGAAGGAACCTCTT 120
61 CACATACAGAAATTTGATTAAGAAAGAGGAAAGGGAAGGAAGGAACCTCTT 120
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
181 GCAATACATGCAAAACAGGACCTGCTGCTTAAAGAAATCCCTATTAATACAGA 240
181 GCAATACATGCAAAACAGGACCTGCTGCTTAAAGAAATCCCTATTAATACAGA 240
181 GCAATACATGCAAAACAGGACCTGCTGCTTAAAGAAATCCCTATTAATACAGA 240
241 AAAGCACTCCACATCTCTGTAAGTGAAGTGAAGCAAGCAAGCAAGCAAGCAAG 300
241 AAAGCACTCCACATCTCTGTAAGTGAAGTGAAGCAAGCAAGCAAGCAAGCAAG 300
241 AAAGCACTCCACATCTCTGTAAGTGAAGTGAAGCAAGCAAGCAAGCAAGCAAG 300
301 CTTTGGATTTTCAAGATTTTGGCACTCTTGGATTAATCTTTTACAGTCAATTA 360
301 CTTTGGATTTTCAAGATTTTGGCACTCTTGGATTAATCTTTTACAGTCAATTA 360
301 CTTTGGATTTTCAAGATTTTGGCACTCTTGGATTAATCTTTTACAGTCAATTA 360
361 GGGGAATTAACGACATTAATTT 383
361 GGGGAATTAACGACATTAATTT 383

RESULT 2
B1820748 463 bp mRNA 1 linear EST 04-OCT-2001
LOCUS B1820748 603034344F1 NIH_MGC_115 Homo sapiens cDNA clone IMAGE:517586 5',
DEFINITION mRNA sequence.
ACCESSION B1820748
VERSION B1820748.1 GI:15932298
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 463)
AUTHORS NIH-MGC <http://mgc.ncl.nih.gov/>.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
CONTACT: Robert Strausberg, Ph.D.
Email: cgapbs-rt@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
<http://image.llnl.gov>
Plate: LLAM1437 row: 9 column: 11
High quality sequence stop: 463.
Location/Qualifiers
1. 463

FEATURES

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:517586"
/clone.lib="NIH_MGC_115"
/lab_host="DH10B"
/note="Organ: pooled brain, lung, testis; Vector:
pCMV-SPORT6; Site 1: NotI; Site 2: EcoRV (destroyed); RNA
source anonymous pool of 6 male brains, age 69. Library is
male lung, age 27; and 1 male testis, age 69. Library is
oligo-dT primed and directionally cloned (EcoRV site is
destroyed upon cloning). Average insert size 1.8 kb,
insert size range 1-3 kb. Library is normalized and
enriched for full-length clones and was constructed and
Gruber (Invitrogen). Research Genetics tracking code
021. Note: this is a NIH-MGC Library."

BASE COUNT 129 a 93 c 78 g 163 t
ORIGIN

Query Match 86.4% Score 330.8; DB 13; Length 463;
Best Local Similarity 97.9%; Pred. No. 1.6e-78;
Matches 376; Conservative 0; Mismatches 4; Indels 4; Gaps 4;

1 CACAGGAACAATCTTTTATGTACATGGAGAAATGACCCCTGCTGCTCAAGTG 60
428 CACAGGAACAATCTTTTATGTACATGGAGAAATGACCCCTGCTGCTCAAGTG 369
61 CACATACAGAAATTTGATTAAGAAAGAGGAAAGGGAAGGAAGGAACCTCTT 120
61 CACATACAGAAATTTGATTAAGAAAGAGGAAAGGGAAGGAAGGAACCTCTT 120
368 CACATACAGAAATTTGATTAAGAAAGAGGAAAGGGAAGGAAGGAACCTCTT 120
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
121 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 180
309 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 251
309 GAGTCCAAATGTCACAAACAAATGTAAGATTTCTTCAAGCAAGGCAATTTT 251
181 GCAATACATGCAAAACAGGACCTGCTGCTTAAAGAAATCCCTATTAATACAGA 240
181 GCAATACATGCAAAACAGGACCTGCTGCTTAAAGAAATCCCTATTAATACAGA 240
250 GCAATACATGCAAAACAGGACCTGCTGCTTAAAGAAATCCCTATTAATACAGA 191
241 AAAGCACTCCACATCTCTGTAAGTGAAGTGAAGCAAGCAAGCAAGCAAGCAAG 300
241 AAAGCACTCCACATCTCTGTAAGTGAAGTGAAGCAAGCAAGCAAGCAAGCAAG 300
190 AAAGCACTCCACATCTCTGTAAGTGAAGTGAAGCAAGCAAGCAAGCAAGCAAG 300
301 CTTTGGATTTTCAAGATTTTGGCACTCTTGGATTAATCTTTTACAGTCAATTA 359
301 CTTTGGATTTTCAAGATTTTGGCACTCTTGGATTAATCTTTTACAGTCAATTA 359
130 CTTTGGATTTTCAAGATTTTGGCACTCTTGGATTAATCTTTTACAGTCAATTA 71
360 AGGGGAATTAACGACATTAATTT 383
70 A-GAGAAATTAACGACATTAATTT 48

RESULT 3
B1715336 465 bp mRNA 1 linear EST 19-SEP-2001
LOCUS B1715336
DEFINITION 1C31F12.1 Homo sapiens cDNA 5' mRNA sequence.
ACCESSION B1715336
VERSION B1715336.1 GI:1591031
KEYWORDS EST.

in SEP ID NO: 1549
Tue May 27 08:34:34 2003

us-09-954-

CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilms' tumour.
XX
SQ Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;

Query Match

Best Local Similarity 99.2%; Score 380; DB 24; Length 383;
Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CACAGAACAAATCTTTTATTGATGAGAAATAGCCCTGTGTGCTGTTCAAGTG	60
DB	1	CACAGAACAAATCTTTTATTGATGAGAAATAGCCCTGTGTGCTGTTCAAGTG	60
QY	61	CAACATACAGATATTTGAATTAAGAAAAGAGGGAACGGGGAGGGAAGGAAGAAACCTCTT	120
DB	61	CAACATACAGATATTTGAATTAAGAAAAGAGGGAACGGGGAGGGAAGGAAGAAACCTCTT	120
QY	121	GAGGTCCAAAGTTGNCACAAAAAATGTAAGATTCTCACGCAAGANGCATTTT	180
DB	121	GAGGTCCAAAGTTGNCACAAAAAATGTAAGATTCTCACGCAAGANGCATTTT	180
QY	181	GCAATACCATGCAAAACAGGAGCTGTGCTTAAAGAAATCCTATTAATTAACAGA	240
DB	181	GCAATACCATGCAAAACAGGAGCTGTGCTTAAAGAAATCCTATTAATTAACAGA	240
QY	241	AAAGACACTCCAGATTTCTGTAGTGAAGTCAAGACACAGAGAAAGAACTAAATG	300
DB	241	AAAGACACTCCAGATTTCTGTAGTGAAGTCAAGACACAGAGAAAGAACTAAATG	300
QY	301	CTTTTGGATTTCAAGATTTTGGCACTCTTGATTAATTTTAAAGTCAATTAAG	360
DB	301	CTTTTGGATTTCAAGATTTTGGCACTCTTGATTAATTTTAAAGTCAATTAAG	360
QY	361	GGGGAATTAAGTCAATTAATTT	383
DB	361	GGGGAATTAAGTCAATTAATTT	383

ALIGNMENTS

for SEQ ID NO: 1549

RESULT 1
 ABL62348 standard; DNA: 383 BP.
 ID ABL62348;
 AC ABL62348;
 XX
 DT 15-MAY-2002 (first entry)
 XX
 DE Colon adenocarcinoma related gene sequence SEQ ID NO:685.
 XX
 KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
 KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
 KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
 KW gene; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200194629-A2.
 XX
 PD 13-DEC-2001.
 XX
 PF 30-MAY-2001; 2001WO-US10838.
 XX
 PR 05-JUN-2000; 2000US-209473P.
 PR 05-JUN-2000; 2000US-209531P.
 PR 18-SEP-2000; 2000US-233133P.
 PR 18-SEP-2000; 2000US-233617P.
 PR 20-SEP-2000; 2000US-234009P.
 PR 20-SEP-2000; 2000US-234034P.
 PR 20-SEP-2000; 2000US-234052P.
 PR 22-SEP-2000; 2000US-234509P.
 PR 22-SEP-2000; 2000US-234567P.

PR	25-SEP-2000	2000US-234923P
PR	25-SEP-2000	2000US-234924P
PR	25-SEP-2000	2000US-235077P
PR	25-SEP-2000	2000US-235082P
PR	25-SEP-2000	2000US-235134P
PR	25-SEP-2000	2000US-235280P
PR	26-SEP-2000	2000US-235637P
PR	26-SEP-2000	2000US-235638P
PR	27-SEP-2000	2000US-235711P
PR	27-SEP-2000	2000US-235720P
PR	27-SEP-2000	2000US-235840P
PR	27-SEP-2000	2000US-235863P
PR	28-SEP-2000	2000US-236028P
PR	28-SEP-2000	2000US-236032P
PR	28-SEP-2000	2000US-236033P
PR	28-SEP-2000	2000US-236034P
PR	28-SEP-2000	2000US-236109P
PR	28-SEP-2000	2000US-236111P
PR	29-SEP-2000	2000US-236842P
PR	29-SEP-2000	2000US-236891P
PR	02-OCT-2000	2000US-237172P
PR	02-OCT-2000	2000US-237173P
PR	02-OCT-2000	2000US-237178P
PR	02-OCT-2000	2000US-237294P
PR	02-OCT-2000	2000US-237294P
PR	02-OCT-2000	2000US-237295P
PR	02-OCT-2000	2000US-237316P
PR	03-OCT-2000	2000US-237425P
PR	03-OCT-2000	2000US-237598P
PR	03-OCT-2000	2000US-237604P
PR	03-OCT-2000	2000US-237606P
PR	03-OCT-2000	2000US-237608P
PR	01-NOV-2000	2000US-244867P
PR	01-NOV-2000	2000US-245084P

PA (AVAL-) AVALON PHARM
XX
PI Young PE, Augustus M, Carter KC, Edner R, Endress G, Horrigan S,
PI Soppet DR, Weaver Z;
XX
DR WPI: 2002-188254/24.
XX
PT Screening for anti-neoplastic agent involves exposing cells to a
PT chemical agent to be tested for anti-neoplastic activity, and
PT determining a change in expression of a gene of a signature gene set
XX
PS Claim 1; SEQ ID 685; 44pp: English.

CC The pretest invention describes a method (M1) for screening for an
CC anti-neoplastic agent. The method involves exposing cells to a chemical
CC agent to be tested for anti-neoplastic activity, determining a change in
CC expression of at least one gene (1) of a signature gene set, where (1)
CC comprises a sequence (S) selected from 8447 sequences (given in ABI6564
CC to ABI70110), or is at least 98% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (1) has cytosolic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer.
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Wilms' tumour.

XX Sequence 383 BF; 139 A; 65 C; 80 G; 96 T; 3 other?

Query Match	99.2%;	Score 380;	DB 24;	Length 383;
Best Local Similarity	100.0%;	Pred. No. 1.8e-100;		
Matches 383;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

1 CACAGGAACAAATTCCTTTATTGTACATTCGAGAAATAGCCCTGTGTGCTGGTTCAGGTG 60

Db	1	CACGGGACATTTCTTTTATTGTGTACATTGGAGAAATAGCCTGTGTCTGGTTCAAGTG	60
QY	61	CAACATCAGAAATTTGAATTAGAAAAAGAGGAACGGGGAAGGAAAGAAACCTCTT	12
Db	61	CAACATCAGAAATTTGAATTAGAAAAAGAGGAACGGGGAAGGAAAGAAACCTCTT	12
QY	121	GAGGTCCAAAGTTGNCACAAAAAATGGTTAAAGATTTCCTACGCAGANGGCATTTT	18
Db	121	GAGGTCCAAAGTTGNCACAAAAAATGGTTAAAGATTTCCTACGCAGANGGCATTTT	18
QY	181	GCAATTCACATGTGAAGAACGACGTGTGTGCTTAAAGAAATCCCTATAAATAACAGA	24
Db	181	GCAATTCACATGTGAAGAACGACGTGTGTGCTTAAAGAAATCCCTATAAATAACAGA	24
QY	241	AAAGACACTCCAGCACTTCCTTACTGTGACATCGACACAGAGAAAGAAATTAAG	30
Db	241	AAAGACACTCCAGCACTTCCTTACTGTGACATCGACACAGAGAAAGAAATTAAG	30
QY	301	CCTTTTGGATTTCAAGATATTGGCACCTCTGTATTACATTTTTTTTACAGTCATTAA	36
Db	301	CCTTTTGGATTTCAAGATATTGGCACCTCTGTATTACATTTTTTTTACAGTCATTAA	36
QY	361	GGGGAATAAACGTACATAATT 383	
Db	361	GGGGAATAAACGTACATAATT 383	

RESULT 2	
ABL65156	
ID	ABL65156 standard; DNA; 383 BP
XX	
AC	ABL65156;

DT 15-MAY-2002 (first entry)

DE Lung cancer related gene sequence SEQ ID NO:3493

KM Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KM stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KM cytosolic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KM gene; ds.

OS Homo sapiens

PN W0200194629-A2

PD 13-DEC-2001.

PF 30-MAY-2001; 2001WO-US10838.

PR 05-JUN-2000; 2000US-209473P.
DE 05-JUN-2000 2000US-209473P

PR 18-SEP-2000; 2000US-233133P;
18-SEP-2000; 2000US-233517D

20-SEP-2000: 2000IS-234034P
20-SEP-2000: 2000US-234009P.

PR 22-SEP-2000; 2000TS-234509P

25-SEP-2000; 2000US-234923P

PR 25-SEP-2000; 2000US-235077P.

PR 25-SEP-2000; 2000US-235134P.

PR 26-SEP-2000; 2000US-235637P.

PR 27-SEP-2000; 2000US-235711P.

PR 27-SEP-2000; 2000US-235840P.

28-SEP-2000; 2000US-236028P.

Claim 1; SEQ ID 3493; 44pp; English.

Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;

```
Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0
```

181 GCAATACCATGCAAAACAGGCGCTGGTGTGCCCTTAAGAGAATCCCTATAATAACAGA 240

Db 361 GGGGATAAACTGACATAATATT 383

ID ABL66239 standard; DNA; 383 BP

DT 15-MAY-2002 (first entry)

DE Lung cancer related gene sequence SEQ ID NO:4576

KM Human, cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
 KM stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
 KM cytotoxic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;
 KM gene; ds.

OS Homo sapiens.

PN WO200194629-A2

PD 13-DEC-2001

PF 30-MAY-2001; 2001WO-US10838

PR 05-JUN-2000; 2000US-209473P.

PR 18-SEP-2000; 2000US-233133P.

PR 20-SEP-2000; 2000US-234009P.

PR 20-SEP-2000; 2000US-234052P.

PR 22-SEP-2000; 2000US-234567P.

PR 25-SEP-2000; 2000US-234924P.

PR 25-SEP-2000; 2000US-235082P.

PR 25-SEP-2000; 2000US-235280P.

PR 26-SEP-2000; 2000US-235638P.

PR 27-SEP-2000; 2000US-235720P.

PR 27-SEP-2000; 200005-235863P.

PR 28-SEP-2000; 2000US-236032P.

PR 28-SEP-2000; 2000US-236034P

PR 28-SEP-2000; 2000US-236111P

PR 29-SEP-2000; 2000US-236891P

PR 02-OCT-2000; 2000US-237173P

PR 02-OCT-2000; 2000US-237294P

PR 02-OCT-2000; 2000US-237316P

PR 03-OCT-2000; 2000US-237598P

PR 03-OCT-2000; 2000US-237604P.
 PR 03-OCT-2000; 2000US-237606P.
 PR 03-OCT-2000; 2000US-237608P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.

(AVALON PHARM.

PI Young PE, Augustus M, Carter KC, Edner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;

XX WPI; 2002-188264/24.

PT Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 PT determining a change in expression of a gene of a signature gene set -
 XX
 PS Claim 1; SEQ ID 4576; 44pp; English.

XX The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664
 CC to ABL70110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC result of M1, and the data is sufficient to convey the chemical
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
 CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
 CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilms' tumour.

XX Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;

Query Match 99.2%; Score 380; DB 24; Length 383;
 Best Local Similarity 100.0%; Pred. No. 1.8e-100;

Matches 383; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

0Y 1 CACAGGAACATCTTTTATGTACATTTGAGAAATAGCCCTGTGCTGTTCAAGTG 60
 1 CACAGGAACATCTTTTATGTACATTTGAGAAATAGCCCTGTGCTGTTCAAGTG 60
 61 CAACATACGAAATTTGAAATTAAGAAAGAGGACGGGGAAGGAAAGAAACCTCTTT 120
 61 CAACATACGAAATTTGAAATTAAGAAAGAGGACGGGGAAGGAAAGAAACCTCTTT 120
 121 GAGGTCCAAAGTTGNCACAAAATGTAAGATTTCTCTACGCAAGANGCATTTT 180
 121 GAGGTCCAAAGTTGNCACAAAATGTAAGATTTCTCTACGCAAGANGCATTTT 180
 121 GAGGTCCAAAGTTGNCACAAAATGTAAGATTTCTCTACGCAAGANGCATTTT 180
 181 GCAAAATACCATGCAAAAGAGGAGCTGTGCTTAAAGAAATCCCTTAATTAACAGA 240
 181 GCAAAATACCATGCAAAAGAGGAGCTGTGCTTAAAGAAATCCCTTAATTAACAGA 240
 241 AAAGACATCTCCAAAGATCTCTGACGTGACAGACAGAGAAAGAAAGAAATG 300
 241 AAAGACATCTCCAAAGATCTCTGACGTGACAGACAGAGAAAGAAAGAAATG 300
 301 CCTTTGGATTTCAAGATATTGGACCTCTTGATTAATTTTAAAGTCAATTA 360
 301 CCTTTGGATTTCAAGATATTGGACCTCTTGATTAATTTTAAAGTCAATTA 360
 361 GGGGAATTAACATGACATTAATTT 383
 361 GGGGAATTAACATGACATTAATTT 383

RESULT 4

ABL66834
 ID ABL66834 standard; DNA; 383 BP.
 XX
 AC ABL66834;
 XX
 DT 15-MAY-2002 (first entry)
 XX
 DE Lung cancer related gene sequence SEQ ID NO:5171.
 XX
 KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
 KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
 KW cytostatic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;
 KW gene; ds.
 XX
 OS Homo sapiens.
 PN W0200194629-A2.
 XX
 PD 13-DEC-2001.
 XX
 PF 30-MAY-2001; 2001WO-US10838.
 XX
 PR 05-JUN-2000; 2000US-209473P.
 PR 05-JUN-2000; 2000US-209531P.
 PR 18-SEP-2000; 2000US-231133P.
 PR 18-SEP-2000; 2000US-233617P.
 PR 20-SEP-2000; 2000US-234009P.
 PR 20-SEP-2000; 2000US-234034P.
 PR 20-SEP-2000; 2000US-234052P.
 PR 22-SEP-2000; 2000US-234509P.
 PR 22-SEP-2000; 2000US-234567P.
 PR 25-SEP-2000; 2000US-234923P.
 PR 25-SEP-2000; 2000US-234924P.
 PR 25-SEP-2000; 2000US-235077P.
 PR 25-SEP-2000; 2000US-235082P.
 PR 25-SEP-2000; 2000US-235134P.
 PR 25-SEP-2000; 2000US-235280P.
 PR 26-SEP-2000; 2000US-235637P.
 PR 26-SEP-2000; 2000US-235638P.
 PR 27-SEP-2000; 2000US-235711P.
 PR 27-SEP-2000; 2000US-235720P.
 PR 27-SEP-2000; 2000US-235840P.
 PR 27-SEP-2000; 2000US-235863P.
 PR 28-SEP-2000; 2000US-236028P.
 PR 28-SEP-2000; 2000US-236032P.
 PR 28-SEP-2000; 2000US-236033P.
 PR 28-SEP-2000; 2000US-236034P.
 PR 28-SEP-2000; 2000US-236109P.
 PR 28-SEP-2000; 2000US-236111P.
 PR 29-SEP-2000; 2000US-236842P.
 PR 29-SEP-2000; 2000US-236891P.
 PR 02-OCT-2000; 2000US-237172P.
 PR 02-OCT-2000; 2000US-237173P.
 PR 02-OCT-2000; 2000US-237278P.
 PR 02-OCT-2000; 2000US-237294P.
 PR 02-OCT-2000; 2000US-237295P.
 PR 02-OCT-2000; 2000US-237316P.
 PR 03-OCT-2000; 2000US-237425P.
 PR 03-OCT-2000; 2000US-237598P.
 PR 03-OCT-2000; 2000US-237604P.
 PR 03-OCT-2000; 2000US-237606P.
 PR 03-OCT-2000; 2000US-237608P.
 PR 01-NOV-2000; 2000US-244867P.
 PR 01-NOV-2000; 2000US-245084P.
 PR
 PA (AVALON PHARM.
 XX
 PI Young PE, Augustus M, Carter KC, Edner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 XX
 DR WPI; 2002-188264/24.
 XX
 PT Screening for anti-neoplastic agent involves exposing cells to a

PT chemical agent to be tested for anti-neoplastic activity, and
 PT determining a change in expression of a gene of a signature gene set
 XX
 PS Claim 1; SEQ ID 5171; 44pp; English.

CC The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in AB16164
 CC to AB170110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which
 CC is the data collected with respect to the anti-neoplastic agent as a
 CC result of M1, and the data is sufficient to convey the chemical
 CC structure and/or properties of the agent. M1 can be used in the
 CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
 CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
 CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
 CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
 CC carcinoma, papillary carcinoma and Wilms' tumour.

XX Sequence 383 BP; 139 A; 65 C; 80 G; 96 T; 3 other;

Query Match 99.2%; Score 380; DB 24; Length 383;

Best Local Similarity 100.0%; Pred. No. 1.8e-100; Mismatches 0; Gaps 0;

Matches 383; Conservative 0; Mismatches 0; Indels 0;

OY 1 CACAGAACATCTTTATTTGATGAGAAATAGCCCTGTGCTGTTCAAGTG 60
 DB 1 CACAGAACATCTTTATTTGATGAGAAATAGCCCTGTGCTGTTCAAGTG 60
 OY 61 CAATATACAGATTTTGAATTAAGAAAGAGGAGCGGGAAGGAAGCAACTCTT 120
 DB 61 CAATATACAGATTTTGAATTAAGAAAGAGGAGCGGGAAGGAAGCAACTCTT 120
 OY 121 GAGTCCAAAGTTCNCAACAAAATGTAAGATTTCCACAGCAAGGCAATTTT 180
 DB 121 GAGTCCAAAGTTCNCAACAAAATGTAAGATTTCCACAGCAAGGCAATTTT 180
 OY 121 GAGTCCAAAGTTCNCAACAAAATGTAAGATTTCCACAGCAAGGCAATTTT 180
 DB 121 GAGTCCAAAGTTCNCAACAAAATGTAAGATTTCCACAGCAAGGCAATTTT 180
 OY 181 GCAATATACATGCAAAACAGGACCTGTGCTGCTTAAGAAATCCTATTAATACAGA 240
 DB 181 GCAATATACATGCAAAACAGGACCTGTGCTGCTTAAGAAATCCTATTAATACAGA 240
 OY 181 GCAATATACATGCAAAACAGGACCTGTGCTGCTTAAGAAATCCTATTAATACAGA 240
 DB 181 GCAATATACATGCAAAACAGGACCTGTGCTGCTTAAGAAATCCTATTAATACAGA 240
 OY 241 AAAAGACACTCCACACATTCCTGTACGTGAGCTGAGACACAGAAAAGAACTAAATG 300
 DB 241 AAAAGACACTCCACACATTCCTGTACGTGAGCTGAGACACAGAAAAGAACTAAATG 300
 OY 301 CTTTGGATTTCAAGATTTTGGACACTCTTGATTAACATTTTTCACAGTCCATTAAA 360
 DB 301 CTTTGGATTTCAAGATTTTGGACACTCTTGATTAACATTTTTCACAGTCCATTAAA 360
 OY 361 GGGGAATTAACCTGACATATAT 383
 DB 361 GGGGAATTAACCTGACATATAT 383

RESULT 5
 ABL67495
 ID ABL67495 standard; DNA; 383 BP.

XX ABL67495;

XX 15-MAY-2002 (first entry)

DE Thyroid cancer related gene sequence SEQ ID NO:5832.

XX Human: cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
 KW stomach; lung; prostate; pancreas; carcinoma; antitumour; carcinos;
 KW cytostatic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;
 KW gene; ds.

OS Homo sapiens.

XX W0200194629-A2.

XX 13-DEC-2001.

PD 30-MAY-2001; 2001WO-US10838.

XX 05-JUN-2000; 2000US-209473P.
 XX 05-JUN-2000; 2000US-209531P.
 XX 18-SEP-2000; 2000US-233133P.
 XX 18-SEP-2000; 2000US-233617P.
 XX 20-SEP-2000; 2000US-234099P.
 XX 20-SEP-2000; 2000US-234034P.
 XX 20-SEP-2000; 2000US-234052P.
 XX 22-SEP-2000; 2000US-234509P.
 XX 22-SEP-2000; 2000US-234567P.
 XX 25-SEP-2000; 2000US-234923P.
 XX 25-SEP-2000; 2000US-234924P.
 XX 25-SEP-2000; 2000US-235077P.
 XX 25-SEP-2000; 2000US-235082P.
 XX 25-SEP-2000; 2000US-235134P.
 XX 25-SEP-2000; 2000US-235280P.
 XX 26-SEP-2000; 2000US-235637P.
 XX 26-SEP-2000; 2000US-235638P.
 XX 27-SEP-2000; 2000US-235711P.
 XX 27-SEP-2000; 2000US-235720P.
 XX 27-SEP-2000; 2000US-235840P.
 XX 27-SEP-2000; 2000US-235863P.
 XX 28-SEP-2000; 2000US-236028P.
 XX 28-SEP-2000; 2000US-236032P.
 XX 28-SEP-2000; 2000US-236033P.
 XX 28-SEP-2000; 2000US-236034P.
 XX 28-SEP-2000; 2000US-236109P.
 XX 28-SEP-2000; 2000US-236111P.
 XX 29-SEP-2000; 2000US-236842P.
 XX 29-SEP-2000; 2000US-236891P.
 XX 02-OCT-2000; 2000US-237172P.
 XX 02-OCT-2000; 2000US-237173P.
 XX 02-OCT-2000; 2000US-237278P.
 XX 02-OCT-2000; 2000US-237294P.
 XX 02-OCT-2000; 2000US-237295P.
 XX 02-OCT-2000; 2000US-237316P.
 XX 02-OCT-2000; 2000US-237425P.
 XX 03-OCT-2000; 2000US-237598P.
 XX 03-OCT-2000; 2000US-237604P.
 XX 03-OCT-2000; 2000US-237606P.
 XX 03-OCT-2000; 2000US-237608P.
 XX 01-NOV-2000; 2000US-244867P.
 XX 01-NOV-2000; 2000US-245084P.
 XX (AVALON) AVALON PHARM.
 XX Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;
 PI Soppet DR, Weaver Z;
 PI MPI; 2002-188264/24.
 XX Screening for anti-neoplastic agent involves exposing cells to a
 PT chemical agent to be tested for anti-neoplastic activity, and
 PT determining a change in expression of a gene of a signature gene set
 XX Claim 1; SEQ ID 5832; 44pp; English.

XX The present invention describes a method (M1) for screening for an
 CC anti-neoplastic agent. The method involves exposing cells to a chemical
 CC agent to be tested for anti-neoplastic activity, determining a change in
 CC expression of at least one gene (I) of a signature gene set, where (I)
 CC comprises a sequence (S) selected from 8447 sequences (given in AB16164
 CC to AB170110), or is at least 95% identical to (S), where a change in
 CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
 CC activity and can be used in gene therapy. M1 can be used for screening
 CC an anti-neoplastic agent, and can be used for producing a product which

for SEDA ID No: 1979

Tue May 27 08:34:37 2003

us-09-954-4

RESULT 1					
T87560					
LOCUS	T87560	550 bp	MRNA	linear	EST 17-MAR-1995
DEFINITION	Y083310.1	Soares fetal liver spleen	INFLS	Homo sapiens	CDNA clone
IMAGE:	114811.5'	mRNA sequence.			

ACCESSION	T87560	GI:715912
VERSION	T87560.1	
KEYWORDS	EST.	
SOURCE	human.	

ORGANISM Homo sapiens

REFERENCE AUTHORS

TITLE
JOURNAL
COMMENT

Homo sapiens; Chordata; Craniata; Vertebrata; Euteleostomi;
 Eukaryota; Metazoa; Primates; Catarrhini; Hominoidea; Homo.
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 1 (bases 1 to 550)
 Hillier, L., Clark, N., Duboue, T., Elliston, K., Hawkins, M., Holman
 M., Hultman, M., Kucab, T., Le, M., Lennon, G., Marra, M., Parsons, J.,
 Rifkin, L., Roifling, T., Soares, M., Tan, F., Trevasakis, E., Waterston
 R., Williamson, A., Woldmann, P. and Wilson, R.
 The WashU-Merck EST Project
 Unpublished (1995)
 Contact: Wilson RK
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: estewartson.wustl.edu
 Insert Size: 1110
 High quality sequence stops: 324 Source: IMAGE Consortium, LNL
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.

```

Insert Length: 1110      Std Error: 0.00
Seq primer: M13Rpr1
High quality sequence stop: 324.
location/Qualifiers
1..550

```

BASE COUNT	ORIGIN
131 a	108 c
117 g	182 t
12 others	

Query Match	97.8%;	Score 538;	DB 14;	Length 550;
Best Local Similarity	100.0%;	Pred. No. 1.8e-129;		
Matches 549;	Conservative 0;	Mismatches 0;		

[illegible]

for SEQ ID NO: 1979

RESULT 1
ABL66669
ID ABL66669 standard; DNA; 550 BP.
XX
AC ABL66669;
XX
DT 15-MAY-2002 (first entry)
XX
DE Lung cancer related gene sequence SEQ ID NO:5006.
XX
KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200194629-A2.
XX
PD 13-DEC-2001.
XX
PF 30-MAY-2001; 2001WO-US10838.
XX
PR 05-JUN-2000; 2000US-209473P.
PR 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.

continue →

RESULT 2
AM275150
LOCUS
DEFINITION
xv76c12.x1 NCI-CGAP_Lu28 Homo sapiens cdna clone IMAGE:2819062 3',
AM275150
ACCESSION
AM275150
VERSION
AM275150.1 GI:6662180
KEYWORDS
EST.
SOURCE
human.
ORGANISM
Homo sapiens
REFERENCE
1 (bases 1 to 405)
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
AUTHORS
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
Tumor Gene Index
JOURNAL
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov

Tissue Procurement: Chris Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D. CDNA Library Preparation: Life
Technologies, Inc. CDNA Library Arrayed by: Christa Prange, The
I.M.A.G.E. Consortium DNA Sequencing by: Washington University
Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.lnl.gov/bdip/image/image.html
Seq primer: -40up from gbco
High quality sequence stop: 404.
1. 405
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2819062"
/clone_lib="NCI-CGAP_Lu28"
/tissue_type="two pooled squamous cell carcinomas"
/lab_host="DH10B"
/note="Organ: Lung; Vector: PCMV-SPT6; Site: 1; Salt:
site_2: Not; Cloned unidirectionally. Primer: Oligo dT.
Library constructed by Life Technologies."

BASE COUNT
122 a 77 c 72 g 134 t

Query Match 97.0%; Score 356; DB 10; Length 405;
Best Local Similarity 99.7%; Pred. No. 7; Le-89;
Matches 367; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 TTGAGGAAATGAGCAATTTATTCATATAAAGAGAAAGCAATTAATTTGCTCAGATGGGAA 60
DB 5 TTGAGGAAATGAGCAATTTATTCATATAAAGAGAAAGCAATTAATTTGCTCAGATGGGAA 64
QY 61 AAAATGAACCTCAAGAGTTGCTTACATTTTAACTGTATATCCCATTTTATCTCTGACAGATGTC- 119
DB 65 AAAATGAACCTCAAGAGTTGCTTACATTTTAACTGTATATCCCATTTTATCTCTGACAGATGTC 124
QY 120 TTATCTCAGTGTCTCTCAATTCACACCTAAATAATTAATTAATTAATTAATTAATTAATTAATTA 179
DB 125 TTATCTCAGTGTCTCTCAATTCACACCTAAATAATTAATTAATTAATTAATTAATTAATTAATTA 184
QY 180 TTGCTTGCATATGCTGATTTAGGGAGAGACTTCTACACCACTCCTCTCTCTCTCTCTCTCTCTCC 239
DB 185 TTGCTTGCATATGCTGATTTAGGGAGAGACTTCTACACCACTCCTCTCTCTCTCTCTCTCTCTCC 244
QY 240 TAAATACCTTTTGTACCTTTGTACACCTTACATATTTGGAATAATGACAGAGGAGGCAAGTGTG 299
DB 245 TAAATACCTTTTGTACCTTTGTACACCTTACATATTTGGAATAATGACAGAGGAGGCAAGTGTG 304
QY 300 CATCAAAAGCAGATTTAGGATTTCCGAATGCTTGAAGGATTTATTTTAAATGAGGAGGCAAGTGTCT 359
DB 305 CATCAAAAGCAGATTTAGGATTTCCGAATGCTTGAAGGATTTATTTTAAATGAGGAGGCAAGTGTCT 364
QY 360 ATTGAATC 367
DB 365 ATTGAATC 372

RESULT 3
LOCUS
DEFINITION
646908.x1 NCI_CGAP_Gas4 Homo sapiens cDNA clone IMAGE:2183102 3',
EST 12-MAY-1999
ACCESSION
A1521564
VERSION
A1521564.1 GI:4435699
KEYWORDS
EST,
SOURCE
human,
ORGANISM
Homo sapiens
REFERENCE
Mammalia; Euthera; Primates; Chordata; Craniata; Vertebrata; Euteleostomi;
I (bases 1 to 416)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index

JOURNAL
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.lnl.gov/bbrp/image/image.html
Insert Length: 4578 Std Error: 0.00
Seq primer: -400P from gibco
High quality sequence stop: 371
POLYA=NO.
FEATURES
Location/Qualifiers
1. 416
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2183102"
/clone_lib="NCI_CGAP_Gas4"
/tissue_type="poorly differentiated adenocarcinoma with
signet ring cell features"
/lab_host="DH10B"
/note="Organ: stomach; Vector: pCMV-SPORT6; Site_1: SalI;
Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT;
Average insert size 1.69 kb. Life Technologies catalog #:
11549-011"
BASE COUNT
120 a 80 c 75 g 141 t
ORIGIN

Query Match 97.0%; Score 356; DB 9; Length 416;
Best Local Similarity 99.7%; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
1 TTTAGGAATGAGGCAATTTTATTTTCAATTAAGAGAAAGCAATTAATTTTGGCTACAGTGGGAA 60
DB |||||
30 TTTAGGAATGAGGCAATTTTATTTTCAATTAAGAGAAAGCAATTAATTTTGGCTACAGTGGGAA 89
DB |||||
61 AAAATGGAACCTCAAGAGTGGCTTACATTTTAACTGTTATCCCTCCCTTATCTCTGACAGATGTC- 119
OY |||||
90 AAAATGGAACCTCAAGAGTGGCTTACATTTTAACTGTTATCCCTCCCTTATCTCTGACAGATGTC 149
DB |||||
120 TTATCTCAGTGTCTCAATTTGACACACTAAATTTGAAATGAGAAATACACCGTGGCTGA 179
OY |||||
150 TTATCTCAGTGTCTCAATTTGACACACTAAATTTGAAATGAGAAATACACCGTGGCTGA 209
DB |||||
180 TTGCTTGACATGTCTGATTTTGGGAGAGACTTCTTACAAACCACTCCCTCTCTTTTCTCCAG 235
OY |||||
210 TTGCTTGACATGTCTGATTTTGGGAGAGACTTCTTACAAACCACTCCCTCTCTTTTCTCCAG 269
DB |||||
240 TAAATACCTTTTGGACTTTGACACACTTACCAATTTGGAATGAGAGGAGGAGGAGGAGTGA 299
OY |||||
270 TAAATACCTTTTGGACTTTGACACACTTACCAATTTGGAATGAGAGGAGGAGGAGGAGTGA 329
DB |||||
300 CATCAAAAGCAGTTAGGATTTGGAATGCTTGAAGGATTAATTTTAAATGAGAGGAGTCT 359
OY |||||
330 CATCAAAAGCAGTTAGGATTTGGAATGCTTGAAGGATTAATTTTAAATGAGAGGAGTCT 389
DB |||||
360 ATTGAATC 367
OY |||||
390 ATTGAATC 397
DB |||||

```

Query Match
Best Local Similarity      100.0%; Score 367; DB 24; Length 367;
Matches 367; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

cells - patient that are differentially regulated compared to normal prostate

Page 570 10 No 2032

AA	
AC	ABL66722;
XX	
DT	15-MAY-2002 (first entry)
XX	
DE	Lung cancer related gene sequence SEQ ID NO:5059
XX	

Homo sapiens.
WO200194629-A2.

PPD	13-DEC-2001.
XX	
PPF	30-MAY-2001; 2001WO-US10838.
XX	

05-JUN-2000; 2000US-209473P.
05-JUN-2000; 2000US-209531P.
18-SEP-2000; 2000US-233133P.
18-SEP-2000; 2000US-233617P.
30-SEP-2000; 2000US-233617P.

22-SEP-2000; 2000UTS-234509P
20-SEP-2000; 2000UTS-234032P
20-SEP-2000; 2000UTS-234054P
22-SEP-2000; 2000UTS-234509P
22-SEP-2000; 2000UTS-234567P

PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235083P.

[illegible]

PR 27-SEP-2000; 2000US-235720P.
PR 27-SEP-2000; 2000US-235840P.
PR 27-SEP-2000; 2000US-235863P.
PR 28-SEP-2000; 2000US-236028P.

PR 28-SEP-2000; 2000US-236032P.
PR 28-SEP-2000; 2000US-236033P.
PR 28-SEP-2000; 2000US-236034P.
PR 28-SEP-2000; 2000US-236109P.
PR 28-SEP-2000; 2000US-236110P.

28-SEP-2000; 2000US-236111P
29-SEP-2000; 2000US-236842P
29-SEP-2000; 2000US-236891P
02-OCT-2000; 2000US-237172P
02-OCT-2000; 2000US-237173P

02-OCT-2000; 2000US-237278P.
02-OCT-2000; 2000US-237294P.
02-OCT-2000; 2000US-237295P.
02-OCT-2000; 2000US-237316P.

03-OCT-2000; 2000US-237425P.
03-OCT-2000; 2000US-237598P.
03-OCT-2000; 2000US-237604P.
03-OCT-2000; 2000US-237606P.
03-OCT-2000; 2000US-237607P.

XX	
RR	01-NOV-2000; 2000US-245084P.
RR	01-NOV-2000; 2000US-244867P.
CC	01-NOV-2000; 2000US-237608P.
AA	(AVAL-) AVALON PHARM.

X Young PE, Augustus M, Carter
I
I
I Soppet DR, Weaver Z;
X

Screening for anti-neoplastic chemical agent to be tested for determining a chemical agent to be tested for

The present invention describes

anti-neoplastic agent. The method involves exposing cells to a chemical agent to be tested for anti-neoplastic activity, determining a change in expression of at least one gene (I) of a signature gene set, where (I)

us-09-954-4:

CC compress a sequence (S) selected from 8447 sequences (given in AB01564
CC to AB070110), or is at least 9% identical to (S), where a change in
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic
CC activity and can be used in gene therapy. M1 can be used for screening
CC an anti-neoplastic agent, and can be used for producing a product which
CC is the data collected with respect to the anti-neoplastic agent as a
CC result of M1, and the data is sufficient to convey the chemical
CC structure and/or properties of the agent. M1 can be used in the
CC treatment of cancer such as colon, breast, stomach, lung, thyroid,
CC oesophageal, ovarian, kidney, prostate or pancreatic cancer,
CC adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer,
CC infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine
CC carcinoma, papillary carcinoma and Milm's tumour.

Query Match	100.0%;	Score 367;	DB 24;	Length 367;
Best Local Similarity	100.0%;	Pred. No. 2.7e-97;		
Matches 367;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0.

1 TTTCGAGGATGCAATTTATTTCATTAAGAGAAACATTATTTCTACAGTGGAA 60

1 TTTCGAGGAATGACCAATTTTATTTCATTAAGAGAAAGACATTAAATTTTGGCTACAGTGGCAA 60

61 AAGAGGACCTCAGAGCTTCTACTTTAACTGTATCCCATTTATCTCTGCAGATGCTCT 120

121 TATTCAGTGTCTCAATTCACACTAAATATTTGATGAGAAATACACCACGTTGGCTGAT 180

121 TATCTCAGTGTCTCAATTCACACTTAATAATTGATGAGAAATACACCACGCTGGCTGAT 180

181 TGCCTGACATGCTCTGATTAGGGAGACTTCTAACCACTCCTCTTTTCTCCCACT 240

241 AAATACCTTTGACTTTGACACCTACCATATTTGAAATGACAGGTGCCCCGAGGGCAAGTCC 300

DB 241 AAATACCTTTGACACCTACCATATTTGAAATGACAGGTGCCCCGAGGGCAAGTTC 300

301 ATCAAGCAGTATGAGATTCGAATGCTTGCTAAGGATTAATTTTAAAGGACACILCA 300

QY 361 TTGATC 367
|||||

Db 361 TTGAATC 367